Studies have demonstrated that ARID1A synergizes with MYCN amplification to drive the transition of tumor cells from an adrenergic to a mesenchymal phenotype, thereby enhancing invasive and migratory capacities and accelerating disease progression. Here, MYCN is linked to neoplasm.